Kidney Cancer Clinical Trial

Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC

Summary

A clinical trial to compare the effectiveness of savolitinib plus durvalumab versus sunitinib in MET-driven (hepatocyte growth factor receptor), unresectable and locally advanced or metastatic PRCC (Papillary Renal Cell Carcinoma)

View Full Description

Full Description

This is a Phase III, randomised, open label, 3 arm, multi-centre, international study assessing the efficacy and safety of savolitinib plus durvalumab compared with sunitinib in participants with MET-driven (without co-occurring FH mutations), unresectable and locally advanced or metastatic PRCC, who have not received any prior systemic anti-cancer therapy in the metastatic setting. The study will also investigate the contribution of durvalumab to the savolitinib plus durvalumab combination.

Approximately 200 participants will be randomised in a 2:1:1 ratio to one of the following intervention groups: savolitinib (600mg, oral, once daily) plus durvalumab (1500mg IV Q4W), sunitinib (50mg, oral, once daily for 4 consecutive weeks, followed by a sunitinib-free interval of 2-weeks, Q6W), or durvalumab monotherapy (1500mg IV Q4W).

Participants will continue to receive study intervention until objective radiological PD per RECIST 1.1 is assessed by the investigator, unacceptable toxicity occurs, consent is withdrawn or another discontinuation criterion is met.

Depending on the preferred subsequent therapy, participants randomised to the durvalumab monotherapy arm will be eligible to switch to receive savolitinib in combination with durvalumab at the time of objective radiological PD assessed by BICR per RECIST 1.1, without any intervening systemic anti-cancer therapy following discontinuation of durvalumab monotherapy.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Histologically confirmed unresectable and locally advanced or metastatic PRCC
PRCC must be centrally confirmed as MET-driven using a sponsor-designated central laboratory validated NGS assay
No prior systemic anti-cancer treatment in the metastatic setting; no prior exposure to MET inhibitors, Durvalumab or Sunitinib in any setting
Karnofsky Score >70
At least one lesion, not previously irradiated, that can be accurately measured at baseline
Adequate organ and bone marrow function
Life expectancy ≥12weeks at Day 1

Exclusion Criteria:

History of liver cirrhosis of any origin and clinical stage; or history of other serious liver disease or chronic disease with relevant liver involvement, with or without normal LFTs
Spinal cord compression or brain metastases, unless asymptomatic and stable on treatment for at least 14 days prior to study intervention
Active or prior cardiac disease (within past 6 months) or clinically significant ECG abnormalities and/or factors/medications that may affect QT and/or QTc intervals
Active infection including HIV, TB, HBV and HCV
Active or prior documented autoimmune or inflammatory disorders
Receipt of live attenuated vaccine within 30 days prior to the first dose of study intervention

Study is for people with:

Kidney Cancer

Phase:

Phase 3

Estimated Enrollment:

220

Study ID:

NCT05043090

Recruitment Status:

Recruiting

Sponsor:

AstraZeneca

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 178 Locations for this study

See Locations Near You

Research Site
Whittier California, 90603, United States
Research Site
Gurnee Illinois, 60031, United States
Research Site
Columbia Maryland, 21201, United States
Research Site
Boston Massachusetts, 02215, United States
Research Site
New York New York, 10065, United States
Research Site
Bahía Blanca , 8000, Argentina
Research Site
Buenos Aires , C1120, Argentina
Research Site
Caba , C1426, Argentina
Research Site
Ciudad Autónoma Buenos Aires , 1125, Argentina
Research Site
Cordoba , 5000, Argentina
Research Site
La Plata , 1900, Argentina
Research Site
Rosario , S2002, Argentina
Research Site
San Miguel de Tucuman , T4000, Argentina
Research Site
Box Hill , 3128, Australia
Research Site
Macquarie University , 2109, Australia
Research Site
Malvern , 3144, Australia
Research Site
St Leonards , 2065, Australia
Research Site
Belo Horizonte , 30120, Brazil
Research Site
Brasilia , 70200, Brazil
Research Site
Cachoeiro De Itapemirim , 29308, Brazil
Research Site
Criciuma , 88811, Brazil
Research Site
Curitiba , 81520, Brazil
Research Site
Florianopolis , 88020, Brazil
Research Site
Fortaleza , 60130, Brazil
Research Site
Natal , 59075, Brazil
Research Site
Pelotas , 96020, Brazil
Research Site
Porto Alegre , 90020, Brazil
Research Site
Porto Alegre , 90110, Brazil
Research Site
Rio de Janeiro , 22250, Brazil
Research Site
Salvador , 40050, Brazil
Research Site
Sao Paulo , 01327, Brazil
Research Site
Sao Paulo , 05652, Brazil
Research Site
São Jose do Rio Preto , 15090, Brazil
Research Site
Săo Paulo , 01246, Brazil
Research Site
Vitoria , 29043, Brazil
Research Site
Calgary Alberta, T2N 4, Canada
Research Site
Montreal Quebec, H3T 1, Canada
Research Site
Providencia , 75100, Chile
Research Site
Santiago , 75006, Chile
Research Site
Santiago , 84203, Chile
Research Site
Temuco , 48105, Chile
Research Site
Beijing , 10003, China
Research Site
Changsha , 41001, China
Research Site
Changsha , 41001, China
Research Site
Chengdu , 61000, China
Research Site
Chongqing , 40003, China
Research Site
Harbin , 15004, China
Research Site
Jinan , 25001, China
Research Site
Nanchang , 33000, China
Research Site
Nanjing , 21002, China
Research Site
Shanghai , 20003, China
Research Site
Shenyang , 11004, China
Research Site
Tianjin , 30006, China
Research Site
Xi'an , 71006, China
Research Site
Zhengzhou , 45000, China
Research Site
Brno , 625 0, Czechia
Research Site
Hradec Kralove , 500 0, Czechia
Research Site
Olomouc , 775 2, Czechia
Research Site
Praha 10 , 100 3, Czechia
Research Site
Praha 5 , 15000, Czechia
Research Site
Praha 8 , 180 8, Czechia
Research Site
Praha , 140 5, Czechia
Research Site
Bordeaux , 33075, France
Research Site
Nice , 06189, France
Research Site
Toulouse Cedex 9 , 31059, France
Research Site
Villejuif , 94800, France
Research Site
Hamburg , 20246, Germany
Research Site
Hannover , 30625, Germany
Research Site
München , 81377, Germany
Research Site
Tübingen , 72076, Germany
Research Site
Ulm , 89081, Germany
Research Site
Hong Kong , , Hong Kong
Research Site
Shatin , 00000, Hong Kong
Research Site
Bangalore , 56002, India
Research Site
Belagavi , 59001, India
Research Site
Jaipur , 30200, India
Research Site
Kochi , 68202, India
Research Site
Kolkata , 70002, India
Research Site
Mumbai , 40001, India
Research Site
Mysore , 57000, India
Research Site
Nashik , 42200, India
Research Site
Nashik , 42200, India
Research Site
Ashdod , 77476, Israel
Research Site
Haifa , 91096, Israel
Research Site
Jerusalem , 91031, Israel
Research Site
Jerusalem , 91120, Israel
Research Site
Petah Tikva , 49100, Israel
Research Site
Rehovot , 76100, Israel
Research Site
Safed , 13100, Israel
Research Site
Tel-Aviv , 64239, Israel
Research Site
Arezzo , 52100, Italy
Research Site
Avellino , 83100, Italy
Research Site
Bari , 70124, Italy
Research Site
Bologna , 40138, Italy
Research Site
Firenze , 50134, Italy
Research Site
Meldola , 47014, Italy
Research Site
Milano , 20132, Italy
Research Site
Milan , 20141, Italy
Research Site
Napoli , 80131, Italy
Research Site
Padova , 35128, Italy
Research Site
Reggio Emilia , 42123, Italy
Research Site
Tricase , 73039, Italy
Research Site
Verona , 37134, Italy
Research Site
Daejeon , 35015, Korea, Republic of
Research Site
Goyang-si , 10408, Korea, Republic of
Research Site
Incheon , 405-7, Korea, Republic of
Research Site
Seoul , 03080, Korea, Republic of
Research Site
Seoul , 03722, Korea, Republic of
Research Site
Seoul , 05505, Korea, Republic of
Research Site
Seoul , 06351, Korea, Republic of
Research Site
Aguascalientes , 20230, Mexico
Research Site
Cancún , 77500, Mexico
Research Site
Monterrey , 64460, Mexico
Research Site
México , 06100, Mexico
Research Site
Queretaro , 76090, Mexico
Research Site
Toluca De Lerdo , 50090, Mexico
Research Site
Amsterdam , 1105 , Netherlands
Research Site
Arnhem , 6815 , Netherlands
Research Site
Rotterdam , 3045 , Netherlands
Research Site
Gdansk , 80-95, Poland
Research Site
Gdynia , 81-51, Poland
Research Site
Kraków , 30-34, Poland
Research Site
Otwock , 05-40, Poland
Research Site
Poznan , 60-56, Poland
Research Site
Poznań , 60-84, Poland
Research Site
Warsaw , 02-78, Poland
Research Site
Baia Mare , 43029, Romania
Research Site
Cluj Napoca , 40001, Romania
Research Site
Cluj-Napoca , 40064, Romania
Research Site
Constanta , 90059, Romania
Research Site
Craiova , 20009, Romania
Research Site
Craiova , 20034, Romania
Research Site
Iasi , 70010, Romania
Research Site
Arkhangelsk , 16304, Russian Federation
Research Site
Ekaterinburg , 62010, Russian Federation
Research Site
Krasnoyarsk , 64401, Russian Federation
Research Site
Kursk , 30552, Russian Federation
Research Site
Kuzmolovskiy , 18866, Russian Federation
Research Site
Moscow , 11547, Russian Federation
Research Site
Omsk , 64401, Russian Federation
Research Site
Saint Petersburg , 19323, Russian Federation
Research Site
Saint Petersburg , 19775, Russian Federation
Research Site
St-Petersburg , 19624, Russian Federation
Research Site
Singapore , 16961, Singapore
Research Site
Trencin , 91101, Slovakia
Research Site
Barcelona , 08035, Spain
Research Site
Barcelona , 08036, Spain
Research Site
Barcelona , ?0804, Spain
Research Site
Cordoba , 14004, Spain
Research Site
Coruña , 15006, Spain
Research Site
Madrid , 28034, Spain
Research Site
Madrid , 28040, Spain
Research Site
Madrid , 28041, Spain
Research Site
Majadahonda , 28222, Spain
Research Site
Málaga , 29010, Spain
Research Site
Pamplona , 31008, Spain
Research Site
Sabadell , 08208, Spain
Research Site
Sevilla , 41013, Spain
Research Site
Valencia , 46026, Spain
Research Site
Kaohsiung City , 83301, Taiwan
Research Site
Taichung , 40705, Taiwan
Research Site
Tainan , 704, Taiwan
Research Site
Adana , 01120, Turkey
Research Site
Ankara , 06100, Turkey
Research Site
Ankara , 06200, Turkey
Research Site
Ankara , 06590, Turkey
Research Site
Edirne , 22030, Turkey
Research Site
Istanbul , 32098, Turkey
Research Site
Istanbul , 34218, Turkey
Research Site
Istanbul , 34722, Turkey
Research Site
Izmir , 35040, Turkey
Research Site
Karsiyaka , 35575, Turkey
Research Site
Kazımkarabekir , 01230, Turkey
Research Site
Chernivtsі , 58001, Ukraine
Research Site
Dnipropetrovsk , 49005, Ukraine
Research Site
Ivano-Frankivsk , 76008, Ukraine
Research Site
Kharkiv , 61166, Ukraine
Research Site
Kyiv , 02125, Ukraine
Research Site
Poltava , 36011, Ukraine
Research Site
Zaporizhzhia , 69040, Ukraine
Research Site
Zaporizhzhia , 69600, Ukraine
Research Site
Leicester , LE1 5, United Kingdom
Research Site
London , EC1A , United Kingdom
Research Site
London , SW3 6, United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Kidney Cancer

Phase:

Phase 3

Estimated Enrollment:

220

Study ID:

NCT05043090

Recruitment Status:

Recruiting

Sponsor:


AstraZeneca

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.